News

Biocon receives USFDA approval for Pebrilzo?

16-Nov-2026 | 09:11
Used in treatment of HER2-positive breast cancer

Biocon announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo? (pertuzumab-qcay), a biosimilar of the reference product Perjeta? (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon's oncology portfolio.

Shreehas Tambe, CEO & Managing Director, Biocon , said, ?The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon's journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.?